ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016

BURLINGTON, Mass.–(BUSINESS WIRE)– ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and
Head of Research and Development, will present at The Leerink Partners
Rare Disease and Immuno-Oncology Roundtable on September 28^th,
2016, at 4:10 p.m. ET at the Lotte New York Palace in New York, New York.

You can access the live webcast of the presentation via the “Investors &
Media” section of our website, www.arqule.com,
under “Events & Presentations”. A replay of the webcast will be
available shortly after the conclusion of the presentation.

About ArQule

ArQule is a biopharmaceutical company engaged in the research and
development of targeted therapeutics to treat cancers and rare diseases.
Our mission is to discover, develop and commercialize novel small
molecule drugs in areas of high unmet need that will dramatically extend
and improve the lives of our patients. Our clinical-stage pipeline
consists of five drug candidates, all of which are in targeted,
biomarker-defined patient populations, making ArQule a leader among
companies our size in precision medicine. ArQule’s lead product, in
phase 3 clinical development, is tivantinib (ARQ 197), an oral,
selective inhibitor of the c-MET receptor tyrosine kinase, for
second-line treatment of hepatocellular carcinoma in partnership with
Daiichi Sankyo in the West and Kyowa Hakko Kirin in Asia. ArQule’s
proprietary pipeline includes: ARQ 087, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor receptor
(FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology
indications; ARQ 092, a selective inhibitor of the AKT serine/threonine
kinase, in phase 1 for multiple oncology indications as well as
ultra-rare Proteus syndrome, in partnership with the National Institutes
of Health (NIH); ARQ 751, a next generation AKT inhibitor, in phase 1
for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone
analog being evaluated as a promoter of NQO1-mediated programmed cancer
cell necrosis, in phase 1/2 in multiple oncology indications in
partnership with the University of Texas Southwestern Medical Center.
ArQule’s current discovery efforts are focused on the identification and
development of novel kinase inhibitors, leveraging the Company’s
proprietary library of compounds.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160921005086/en/